DS9051b
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Adrenocortical Carcinoma
Conditions
Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Trial Timeline
Nov 4, 2025 → Mar 1, 2028
NCT ID
NCT07189403About DS9051b
DS9051b is a phase 1 stage product being developed by Daiichi Sankyo for Advanced or Metastatic Adrenocortical Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07189403. Target conditions include Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Adrenocortical Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07189403 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced or Metastatic Adrenocortical Carcinoma